2027 Disease Pharmacokinetics 
The Pharma Data
FEBRUARY 8, 2021
RE47,739 (‘739) by more than four years until March 5, 2027. Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with CDK4/6 inhibitors, including IBRANCE when taken in combination with endocrine therapy. The certificate extends the term of U.S. 2,3 In the U.S.,
Drug Target Review
JUNE 5, 2023
It also displayed favourable pharmacokinetics (PK) and is well tolerated in non-human primates (NHP) at exposure levels above those projected to be efficacious. ZW191 also displayed favourable pharmacokinetics (PK) and is well tolerated in non-human primates (NHP) at exposure levels above those projected to be efficacious.
Agency IQ
FEBRUARY 15, 2024
If you’re looking for something specific, we recommend using the search function in your browser (Ctrl-F) to look for keywords of interest.
Expert insights. Personalized for you.
52 
Let's personalize your content